MedTrace Logo

Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy

NCT00505583 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-11-29

No results posted yet for this study

Summary

To evaluate the effects of single oral doses of MOA-728 compared to a positive control in subjects on methadone therapy.

Conditions

  • Methadone-maintenance Subjects

Interventions

DRUG

MOA-728

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Jeff Cohn · Bausch Health Americas, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00505583 on ClinicalTrials.gov